CYTOGENETIC OBSERVATIONS AFTER MEGLUMINE ANTIMONATE THERAPY FOR VISCERAL LEISHMANIASIS

Citation
P. Hantson et al., CYTOGENETIC OBSERVATIONS AFTER MEGLUMINE ANTIMONATE THERAPY FOR VISCERAL LEISHMANIASIS, Pharmacotherapy, 16(5), 1996, pp. 869-871
Citations number
13
Language
INGLESE
art.tipo
Article
Categorie Soggetti
Pharmacology & Pharmacy
Journal title
ISSN journal
0277-0008
Volume
16
Issue
5
Year of publication
1996
Pages
869 - 871
Database
ISI
SICI code
0277-0008(1996)16:5<869:COAMAT>2.0.ZU;2-W
Abstract
Few data are available concerning the genotoxic effects of antimonial salts therapy in humans. A patient suffering from visceral leishmanias is was treated for 15 days with a cumulative dose meglumine antimoniat e 42.5 g. Peripheral blood lymphocytes sampled before treatment, 7 day s later, and at the end of therapy (day 15) were examined for the pres ence of structural chromosome aberrations, sister chromatid exchanges (SCEs), and micronuclei in binucleated cells. The treatment resulted i n an increase of binucleated cells carrying micronuclei, with no chang es in chromosome structural aberrations or in mean SCE frequency. On t he basis of these observations and of experimental results reported in the literature, we. conclude that therapy with meglumine antimoniate apparently does not represent a mutagenic or carcinogenic risk to huma ns.